Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT 1 relugolix study in women with endometriosis-associated pain
2017-001588-19Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- Aug 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tissue-plasminogen activator, estradiol and norethisterone acetate in endometriosis (3 arms), sponsored by Myovant Sciences. Primary endpoint: Dysmenorrhea responder rate at Week 24/EOT. Started Aug 2017; status: completed.
02
Drugs
tissue-plasminogen activatorestradiolnorethisterone acetate
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2017-001588-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001588-19.